Department of Surgery Division of Chest Surgery, Breast and Endocrine Surgery

Chest Surgery
Toshiaki Morikawa, Professor
Tadashi Akiba, Professor
Shuji Sato, Associate Professor
Makoto Odaka. Associate Professor

Breast and Endocrine Surgery
Hiroshi Takeyama, *Professor*Satoki Kinoshita, *Professor*Yasuo Toriumi, *Professor*Kazumi Kawase, *Associate Professor*Hiroko Nogi, *Associate Professor*Isao Tabei, *Assistant Professor*

General Summary

The Divisions of Chest Surgery and of Breast and Endocrinology Surgery were established in June 2005. Since then, all staff members have been active in surgical practice, research, and education. Many studies are ongoing.

Research Activities

Chest Surgery

Thoracoscopic surgery is the focus of our clinical activity. This minimally invasive surgery produces fewer postoperative complications and sequelae and is especially beneficial for elderly, high-risk patients. Thoracoscopic surgery requires advanced skills, and we have independently developed total thoracoscopic surgery, which uses only a thoracoscope and video monitors to provide intraoperative views. Our method of thoracoscopic surgery can be used to treat many chest conditions, such as juvenile pneumothorax, peripheral lung nodules, mediastinal tumors, and lung cancer.

Thoracoscopic surgery is also indicated for higher-risk patients with such complications as advanced pulmonary emphysema, impaired pulmonary function, and extremely high age who are not candidates for conventional open surgery.

Operative procedures, including wedge resection, segmentectomy, lobectomy, and pneumonectomy of the lung, are all safely performed, in addition to resection of mediastinal tumors or the thymus. Surgery for lung cancer requires much more advanced skills and oncological considerations, which have also been independently developed. Of the mediastinal procedures, thymectomy is usually performed via thoracoscopy rather than via a conventional median sternotomy. In our department the percentage of the chest operations performed via thoracoscopy is more than 90%, which we assume to be the highest rate in the world.

The minimal invasiveness of thoracoscopic surgery is being investigated with prospective clinical studies. These studies include a comparative study of open surgery and video-assisted surgery for lung cancer and evaluations of video-assisted surgery for bullous lung diseases in elderly patients with impaired lung function, of video-assisted surgery for thymic tumors, and of video-assisted thymectomy for myasthenia gravis.

Our clinical studies are also evaluating new devices and methods, such as narrow-band imaging for the thoracoscopic diagnosis of benign and malignant lung diseases, and LaparoSonic coagulating shears (Ethicon Endo-Surgery, Inc., Cincinnati, OH, USA) for small thoracotomy. Three-dimensional diagnosis with computed tomography is used to make thoracoscopic surgery safer. The diagnosis and treatment of ground glass opacity of the lung, which is considered to indicate early adenocarcinoma, are being evaluated.

Many basic research studies are also underway. In the morphological expression-related advancement of the molecular genetic analysis of lung cancer, we are investigating whether carcinogenesis of the lung as reflected by CA19-9 activity is an important marker of de novo carcinogenesis. The biological and genetic characteristics of peripheral adenocarcinoma of the lung are being investigated to establish the most appropriate surgical procedures. Correlation with the detection of blood CTC (Circulating Tumor Cells) and the prognosis of the patient with lung cancer is examined.

The oncogene of the lung cancer is analyzed with the next generation sequencer.

A system for viewing videos on the Internet is now being developed which will help improve surgical training and research.

Breast

- 1. Clinical study
- 1) The evaluation of immediate breast reconstruction after neoadjuvant chemotherapy. Experience with immediate breast reconstruction after neoadjuvant chemotherapy is limited. The purpose of our clinical study is to evaluate the oncological safety of this procedure in breast cancer patients after neoadjuvant chemotherapy.
- 2) We are performing multicenter clinical trial to evaluate the oncological safety of the patients with one or two positive-sentinel-node metastases after omission of axillary lymph node dissection.
- 3) Cryotherapy for small breast cancer:

Cryoablation using extremely cold temperatures to destroy tumor tissues has been increasingly recognized as a highly efficient cancer therapy. Therefore, cryotherapy has been used in the clinic to treat several types of tumors, including breast, kidney, liver, esophagus, skin, prostate, lung and bone. Moreover, the efficiency of cryotherapy, combined with its limited side-effects, has been confirmed through pilot studies with early-stage breast cancer patients.

4) Therapeutic strategy for oligometastatic breast cancer

We have analyzed the patients with metastatic breast cancer for thirty years. The analyses indicate that oligometastatic breast cancer is a distinct subgroup with long-term prognosis superior to metastatic breast cancer. We try further prospective studies to better characterize oligometastatic breast cancer to improve prognosis in metastatic breast cancer.

- 5) We also have evaluated the impact of resection of breast tumor among breast cancer patients with distant metastasis on overall survival.
- 2. Basic research
- 1) CTC and DTC

We had investigated clinical values of the presence of circulating tumor cells in the peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of patients

with early breast cancer. Detection of DTC-BMs was useful for observing adjuvant therapy effects and for predicting relatively late-phase metastasis. The cluster status of CTCs suggested early relapsing.

2) Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2): We have evaluated the association between DYRK2 and stem cell or mTOR signal. The ectopic expression of DYRK2 promoted phosphorylation of Thr631 for the ubiquitination and degradation of mTOR. DYRK2 expression levels might thus predict clinical responses to everolimus. Furthermore, DYRK2 was a novel negative regulator for formation of breast cancer stem cells. Downregulation of DYRK2 promoted cancer stem-like traits in vitro, tumourigenesis in vivo and the proportion of the cancer stem cell population in human breast cancer tissues. We found that Krupple-like factor 4 (KLF4) serves as a key mediator of DYRK2's control over the cancer stem phenotype. Reduced DYRK2 expression increased KLF4 expression, which induced cancer stem-like properties. We identified androgen receptor (AR) as a transcription factor binding to the KLF4 promoter region; this process was dependent on DYRK2 kinase activity. Our findings delineated a mechanism of cancer stem cell regulation by the DYRK2-AR-KLF4 axis in breast cancer. Targeting of this pathway might be a promising strategy against breast cancer stem cells.

Endocrine

1. Clinical research

Lenvatinib is one of tyrosine kinase inhibitor, which blocks VEGF Receptor 1-3 kinase. Lenvatinib had developed in Japan, and prolonged the progression free survival (PFF) to, in phase III trial.

We are planning and going a multi-center clinical trial for thyroid carcinomas, including papillary carcinoma, medullary carcinoma, and undifferentiated carcinoma to confirm the antitumor effects of Lenvatinib in thyroid carcinoma treated major facilities of Japan from 2016.

Our department is joining to this trial from 2016. Three cases were already enrolled in this study. This molecularly targeted therapy will be applied for treatment-resistant cancer bearing patients.

2. Basic research

The detection of antigens of thyroid carcinoma in sera.

A monoclonal antibody, designated JT-95, was made against a thyroid papillary carcinoma obtained by our Department of Breast and Endocrine Surgery. We are attempting to measure the antigen recognized by JT-95 in the serum of patients with papillary carcinoma, in collaboration with the Molecular Cell Biology Division of Jikei University. The quantity of antigen of JT-95 is higher in patients with papillary carcinoma, especially those with metastasis to lung or bone, than in patients with breast carcinoma.

We are now trying to make chromatography of JT-95 to detect thyroid carcinoma antigen more easily.

Publications

Morikawa T, Yamashita M, Odaka M, Tsukamoto Y, Shibasaki T, Mori S, Asano H, Akiba T. A step-by-step development of real-size chest model for simulation of thoracoscopic surgery. Interact Cardiovasc Thorac Surg. 2017; 25:

Odaka M, Tsukamoto Y, Shibasaki T, Mori S, Asano H, Yamashita M, Morikawa T. Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma. J Vis Surg. 2017; 3: 54.

Sato T, Morikawa T. Video-assisted thoracoscopic surgery training with a polyvinyl-alcohol hydrogel model mimicking real tissue. *J Vis Surg.* 2017; **3:** 65.

Kinoshita S, Miyake R, Shimada N, Hirano A, Seki Y, Harada J, Kato K, Uchida K, Takeyama H, Morikawa T. Initial experience with contrastenhanced ultrasonography in follow-up assessment of small breast cancer treated by cryoablation. Australas Med J. 2017; 10: 599-606.

Kawase K, Nomura K, Tominaga R, Iwase H, Ogawa T, Shibasaki I, Shimada M, Taguchi T, Takeshita E, Tomizawa Y, Nomura S, Hanazaki K, Hanashi T, Yamashita H, Kokudo N, Maeda K. Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part 1: Working style. Sura Todav. 2018: 48: 33-43.

Nogi H, Uchida K, Mimoto R, Kamio M, Shioya H, Toriumi Y, Suzuki M, Nagasaki E, Kobayashi T, Takeyama H. Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy after neoadjuvant chemotherapy. Clin Breast Cancer. 2017; 17: 644-9.

Tabei I, Tsuchida S, Akashi T, Ookubo K, Hosoda S, Furukawa Y, Tanabe Y, Tamura Y. Effects of a Novel Method for Enteral Nutrition Infusion Involving a Viscosity-regulating Pectin Solution: A Multicenter Randomized Controlled Trial. Clinical Nutrition ESPEN. 2018; 23: 34-40.

Miyake R, Kinoshita S, Shimada N, Uchida K, Takeyama H, Morikawa T. Preservation of the nipple-areola complex in skin-sparing mastectomy for early breast cancer. *Surg Today.* 2018; **48:** 591-7. doi: 10.1007/s00595-018-1633-z. Epub 2018 Feb 21.

Tanaka K, Misawa T, Ashizuka S, Yoshizawa J, Akiba T, Ohki T. Risk factors for incisional hernia in children. World J Surg. 2017. [Epub ahead of print]

Kawahara H, Akiba T, Yanaga K. Cuff-less J pouch anal stapling anastomosis for ulcerative colitis. *Anticancer Res.* 2017; **37:** 5743-5.

Tsunematsu M, Takahashi N, Murakami K, Misawa T, Akiba T, Yanaga K. Successful conversion surgery for gastric cancer with multiple liver metastases treated after S-1 plus cisplatin combination chemotherapy: a case report. *Surg Case Rep.* 2017: **3:** 95.

Tanaka K, Misawa T, Haruki K, Saito R, Gocho T, Akiba T. Enucleation of solid pseudopapillary tumor with a preoperative nasopancreatic drainage stent in a child. *Asian J Endosc Surg.* 2017; **10:** 438-41.

Shukuzawa K, Toya N, Momokawa Y, Fukushima S, Akiba T, Ohki T. Pulmonary embolism due to inferior vena cava compression by a retroperitoneal hematoma after endovascular repair of a ruptured abdominal aortic aneurysm. *Case Rep Vasc Med.* 2017; **2017**: 8172549.

Ito Z, Takakura K, Suka M, Kanai T, Saito R, Fujioka S, Kajihara M, Yanagisawa H, Misawa T, Akiba T, Koido S, Ohkusa T. Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. Oncology Letters. 2017; 13: 4799-805.

Nishie R, Toya N, Fukushima S, Ito E, Murakami Y, Akiba T, Ohki T. Prophylactic accessory renal artery coil embolization for prevention of Type II endoleak following endovascular aneurysm repair: A case report. Surg Case Rep. 2017; 3: 58.

Murakami Y, Toya N, Fukushima S, Ito E, Akiba T, Ohki T. Ascending aorta-common hepatic artery bypass for mesenteric revascularization. Int J Surg Case Rep. 2017; 32: 51-3.